Quick Answer
ProMIS Neurosciences Inc. reported R&D Expense of $33.38 million for fiscal year 2025.
ProMIS Neurosciences Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $33.38M | +213.8% |
| 2024 | $10.64M | +34.9% |
| 2023 | $7.88M | -51.0% |
| 2022 | $16.09M | +247.7% |
| 2021 | $4.63M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $9.80M | +282.1% | +12.0% |
| June 30, 2025 | $8.75M | +438.2% | +60.1% |
| March 31, 2025 | $5.46M | +157.3% | +113.1% |
| September 30, 2024 | $2.56M | +124.5% | +57.7% |
| June 30, 2024 | $1.63M | +61.7% | -23.4% |
| March 31, 2024 | $2.12M | -39.5% | +85.9% |
| September 30, 2023 | $1.14M | -75.0% | +13.6% |
| June 30, 2023 | $1.01M | -68.9% | -71.3% |
- ProMIS Neurosciences Inc. showed an increase of +213.8% in R&D Expense compared to the prior fiscal year.
- Over the 2021–2025 period, ProMIS Neurosciences Inc.’s r&d expense has grown by 621.3% (from $4.63 million to $33.38 million).
- The most recent figure is from ProMIS Neurosciences Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: